What is semaglutide?
Semaglutide acts as a GLP-1 receptor agonist. WEGOVY prescribing information.
Who is covered by WEGOVY's weight-management indication?
The US WEGOVY injection label indicates long-term weight reduction alongside a reduced-calorie diet and increased physical activity for adults and pediatric patients aged 12 years or older with obesity. It also covers adults with overweight and at least one weight-related comorbid condition. WEGOVY prescribing information.
Semaglutide side effects in WEGOVY trials
In the WEGOVY injection placebo-controlled trials in adults with obesity or overweight for weight reduction, nausea, diarrhea, vomiting, constipation and abdominal pain were among reactions reported in at least 2% of WEGOVY-treated participants and more often than with placebo. WEGOVY prescribing information.
Who should not use WEGOVY?
WEGOVY is contraindicated with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2. The prescribing information also lists acute pancreatitis among serious adverse reactions discussed in the label. WEGOVY prescribing information.
Semaglutide and tirzepatide: what differs?
Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at both GIP and GLP-1 receptors. That receptor distinction explains the different descriptions, but does not by itself show which medicine is more effective or suitable for a person. Read the separate tirzepatide guide and the GLP-1 comparison overview. WEGOVY prescribing information, ZEPBOUND prescribing information.
